Hansoh Pharma Wins 2025 NRDL Approval for New Ameile Indications and Renews Multiple Drugs

Reuters12-08 14:07

Hansoh Pharma Wins 2025 NRDL Approval for New Ameile Indications and Renews Multiple Drugs

Hansoh Pharmaceutical Group Co. Ltd. announced that two new indications for its innovative drug Aumolertinib Mesilate Tablets (Ameile®) have been added to the 2025 National Reimbursement Drug List (NRDL) in China. The new indications include treatment for adult patients with stage II to IIIB non-small cell lung cancer (NSCLC) with specific EGFR mutations after tumor resection, and for adult patients with locally advanced, unresectable (stage III) NSCLC with EGFR mutations whose disease has not progressed during or after platinum-based chemoradiotherapy. Additionally, all indications for the company's drugs Saint Luolai (Pegmolesatide Injection) and Hengmu (Tenofovir Amibufenamide Tablets) have been renewed in the 2025 NRDL. The updated NRDL will be implemented on January 1, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on December 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589145381?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 14:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589145381","market":"fut","top_or_hot":-1,"title":"Hansoh Pharma Wins 2025 NRDL Approval for New Ameile Indications and Renews Multiple Drugs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharma Wins 2025 NRDL Approval for New Ameile Indications and Renews Multiple Drugs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hansoh Pharmaceutical Group Co. Ltd. announced that two new indications for its innovative drug Aumolertinib Mesilate Tablets (Ameile®) have been added to the 2025 National Reimbursement Drug List (NRDL) in China. The new indications include treatment for adult patients with stage II to IIIB non-small cell lung cancer (NSCLC) with specific EGFR mutations after tumor resection, and for adult patients with locally advanced, unresectable (stage III) NSCLC with EGFR mutations whose disease has not progressed during or after platinum-based chemoradiotherapy. Additionally, all indications for the company's drugs Saint Luolai (Pegmolesatide Injection) and Hengmu (Tenofovir Amibufenamide Tablets) have been renewed in the 2025 NRDL. The updated NRDL will be implemented on January 1, 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on December 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharma Wins 2025 NRDL Approval for New Ameile Indications and Renews Multiple Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharma Wins 2025 NRDL Approval for New Ameile Indications and Renews Multiple Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-08 14:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharma Wins 2025 NRDL Approval for New Ameile Indications and Renews Multiple Drugs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hansoh Pharmaceutical Group Co. Ltd. announced that two new indications for its innovative drug Aumolertinib Mesilate Tablets (Ameile®) have been added to the 2025 National Reimbursement Drug List (NRDL) in China. The new indications include treatment for adult patients with stage II to IIIB non-small cell lung cancer (NSCLC) with specific EGFR mutations after tumor resection, and for adult patients with locally advanced, unresectable (stage III) NSCLC with EGFR mutations whose disease has not progressed during or after platinum-based chemoradiotherapy. Additionally, all indications for the company's drugs Saint Luolai (Pegmolesatide Injection) and Hengmu (Tenofovir Amibufenamide Tablets) have been renewed in the 2025 NRDL. The updated NRDL will be implemented on January 1, 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on December 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL6BngwZ:1","article_id":"2589145381","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589145381","pubTimestamp":1765174037,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Hansoh Pharmaceutical Group Co. Ltd. announced that two new indications for its innovative drug Aumolertinib Mesilate Tablets  have been added to the 2025 National Reimbursement Drug List  in China. The new indications include treatment for adult patients with stage II to IIIB non-small cell lung cancer  with specific EGFR mutations after tumor resection, and for adult patients with locally advanced, unresectable  NSCLC with EGFR mutations whose disease has not progressed during or after platinum-based chemoradiotherapy. Additionally, all indications for the company's drugs Saint Luolai  and Hengmu  have been renewed in the 2025 NRDL. The updated NRDL will be implemented on January 1, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1589":"北水核心资产","03692":"翰森制药","BK1583":"高瓴概念","BK1191":"制药"},"translate_title":"翰森制药获2025年国家医保目录批准阿美乐新适应症并续约多款药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"Hansoh Pharma Wins 2025 NRDL Approval for New Ameile Indications and Renews Multiple Drugs\n    \n\n        Hansoh Pharmaceutical Group Co. Ltd. announced that two new indications for its innovative drug Aumolertinib Mesilate Tablets (Ameile®) have been added to the 2025 National Reimbursement Drug List (NRDL) in China. The new indications include treatment for adult patients with stage II to IIIB non-small cell lung cancer (NSCLC) with specific EGFR mutations after tumor resection, and for adult patients with locally advanced, unresectable (stage III) NSCLC with EGFR mutations whose disease has not progressed during or after platinum-based chemoradiotherapy. Additionally, all indications for the company's drugs Saint Luolai (Pegmolesatide Injection) and Hengmu (Tenofovir Amibufenamide Tablets) have been renewed in the 2025 NRDL. The updated NRDL will be implemented on January 1, 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on December 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589145381","isCrawlerRequest":true}